Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework. / Irizar, Patricia ; Pars, Danierl; Diderichsen, Finn.

I: EClinicalMedicine, Bind 68, 102360, 2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Irizar, P, Pars, D & Diderichsen, F 2024, 'Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework', EClinicalMedicine, bind 68, 102360. https://doi.org/10.1016/j.eclinm.2023.102360

APA

Irizar, P., Pars, D., & Diderichsen, F. (2024). Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework. EClinicalMedicine, 68, [102360]. https://doi.org/10.1016/j.eclinm.2023.102360

Vancouver

Irizar P, Pars D, Diderichsen F. Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework. EClinicalMedicine. 2024;68. 102360. https://doi.org/10.1016/j.eclinm.2023.102360

Author

Irizar, Patricia ; Pars, Danierl ; Diderichsen, Finn. / Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework. I: EClinicalMedicine. 2024 ; Bind 68.

Bibtex

@article{c71e9b7e4e684126b3f53541f9859444,
title = "Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework",
abstract = "The COVID-19 pandemic has resulted in disproportionate consequences for ethnic minority groups and Indigenous Peoples. We present an application of the Priority Public Health Conditions (PPHC) framework from the World Health Organisation (WHO), to explicitly address COVID-19 and other respiratory viruses of pandemic potential. This application is supported by evidence that ethnic minority groups were more likely to be infected, implying differential exposure (PPHC level two), be more vulnerable to severe disease once infected (PPHC level three) and have poorer health outcomes following infection (PPHC level four). These inequities are driven by various interconnected dimensions of racism, that compounds with socioeconomic context and position (PPHC level one). We show that, for respiratory viruses, it is important to stratify levels of the PPHC framework by infection status and by societal, community, and individual factors to develop optimal interventions to reduce inequity from COVID-19 and future infectious diseases outbreaks.Keywords COVID-19SARS-CoV-2EthnicityRaceIndigenousHealth inequity",
author = "Patricia Irizar and Danierl Pars and Finn Diderichsen",
year = "2024",
doi = "10.1016/j.eclinm.2023.102360",
language = "English",
volume = "68",
journal = "EClinicalMedicine",
issn = "2589-5370",
publisher = "The Lancet Publishing Group",

}

RIS

TY - JOUR

T1 - Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework

AU - Irizar, Patricia

AU - Pars, Danierl

AU - Diderichsen, Finn

PY - 2024

Y1 - 2024

N2 - The COVID-19 pandemic has resulted in disproportionate consequences for ethnic minority groups and Indigenous Peoples. We present an application of the Priority Public Health Conditions (PPHC) framework from the World Health Organisation (WHO), to explicitly address COVID-19 and other respiratory viruses of pandemic potential. This application is supported by evidence that ethnic minority groups were more likely to be infected, implying differential exposure (PPHC level two), be more vulnerable to severe disease once infected (PPHC level three) and have poorer health outcomes following infection (PPHC level four). These inequities are driven by various interconnected dimensions of racism, that compounds with socioeconomic context and position (PPHC level one). We show that, for respiratory viruses, it is important to stratify levels of the PPHC framework by infection status and by societal, community, and individual factors to develop optimal interventions to reduce inequity from COVID-19 and future infectious diseases outbreaks.Keywords COVID-19SARS-CoV-2EthnicityRaceIndigenousHealth inequity

AB - The COVID-19 pandemic has resulted in disproportionate consequences for ethnic minority groups and Indigenous Peoples. We present an application of the Priority Public Health Conditions (PPHC) framework from the World Health Organisation (WHO), to explicitly address COVID-19 and other respiratory viruses of pandemic potential. This application is supported by evidence that ethnic minority groups were more likely to be infected, implying differential exposure (PPHC level two), be more vulnerable to severe disease once infected (PPHC level three) and have poorer health outcomes following infection (PPHC level four). These inequities are driven by various interconnected dimensions of racism, that compounds with socioeconomic context and position (PPHC level one). We show that, for respiratory viruses, it is important to stratify levels of the PPHC framework by infection status and by societal, community, and individual factors to develop optimal interventions to reduce inequity from COVID-19 and future infectious diseases outbreaks.Keywords COVID-19SARS-CoV-2EthnicityRaceIndigenousHealth inequity

U2 - 10.1016/j.eclinm.2023.102360

DO - 10.1016/j.eclinm.2023.102360

M3 - Journal article

C2 - 38545088

VL - 68

JO - EClinicalMedicine

JF - EClinicalMedicine

SN - 2589-5370

M1 - 102360

ER -

ID: 380071524